跳至主要内容
临床试验/NL-OMON42667
NL-OMON42667已完成2 期

Pharmacokinetic evaluation of a pulmonary administered levodopa dry powder formulation in Parkinson*s disease. - Levodopa dry powder inhalation in patients with Parkinson*s disease.

Martini Ziekenhuis0 个研究点目标入组 8 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
入组人数
8

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • - Signed informed consent.;- Diagnosed with Parkinson*s disease;- At least 18 years old. ;- Currently on stable Parkinson*s disease levodopa regimen.;- Require levodopa containing medication regimen with a maximum of 4 administrations a day.;- Able to perform spirometry.

排除标准

  • - Cognitive dysfunction, which precludes good understanding of instructions and/or informed consent.;- Pregnant or breast feeding.;- Active pulmonary disease. ;- Patients with known symptomatic orthostatic hypotension.;- The use of COMT inhibitors and/or MAO-B inhibitors.

研究者

相似试验